Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPsychiatry/Behavioral HealthAetna Electroconvulsive Therapy Coverage Update | …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0445

    Electroconvulsive Therapy

    Customize your policy alerts

    Sign up for Aetna Policy 0445 alerts

    Get alerted when Policy 0445 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medical necessity, coverage, and coding for electroconvulsive therapy for Aetna members, describing covered indications, experimental/investigational uses, and related coding guidance.

    Policy Summary
    PayerAetna
    PolicyElectroconvulsive Therapy
    Policy CodePolicy 0445
    Change TypeNo material change
    Effective DateSep 14, 2000
    Last ReviewSep 21, 2023
    Next Review DateMay 9, 2024
    Key ActionConfirm prior authorization documents member is ≥12, has a qualifying diagnosis, and meets at least one selection criterion (e.g., failed adequate medication trial or urgent need).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6-12average course for depression
    up to 20max typical sessions
    14 studiesC/M-ECT relapse reduction studies
    216patients in dementia agitation reviews
    09/21/2023last review

    Coverage and Medical Necessity Criteria

    Medical Necessity

    Covered when ANY of the following diagnoses are present

    Medically necessary indications: Catatonia

    From policy medical necessity list

    Medically necessary indications: Certain acute schizophrenic exacerbations

    From policy medical necessity list

    Medically necessary indications: Major depressive disorder (unipolar)

    From policy medical necessity list

    Medically necessary indications: Bipolar disorder
    Policy Summary
    PayerAetna
    PolicyElectroconvulsive Therapy
    Policy CodePolicy 0445
    Change TypeNo material change
    Effective DateSep 14, 2000
    Last ReviewSep 21, 2023
    Next Review DateMay 9, 2024
    Key ActionConfirm prior authorization documents member is ≥12, has a qualifying diagnosis, and meets at least one selection criterion (e.g., failed adequate medication trial or urgent need).
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaCoding and Visit LimitsPrior Authorization, Documentation, and Billing GuidanceECT Modalities, Adjuncts, and Predictive AssessmentsInpatient and Outpatient Level of CareKey Definitions

    From policy medical necessity list

    Medically necessary indications: Mania

    From policy medical necessity list

    Treatment Series Limits

    Usage limits and prophylactic use

    Session limits and prophylaxis: More than 20 sessions in a treatment series is rarely medically necessary; additional, less frequent sessions may be used as prophylaxis after remission (initially weekly then tapered to monthly or less).>20 sessions rarely necessary

    Policy guidance on typical series and prophylactic maintenance ECT

    Stopping rules during an index course: Discontinue ECT if a patient with partial but substantial improvement shows no change after 2 additional treatments, or if there is no response after 6 to 10 treatments.no response after 6-10 treatments

    Clinical experience guidance; additional treatments may increase confusion

    Experimental/Investigational

    Considered experimental and investigational

    Experimental approaches: Multiple monitored ECT (MMECT)

    Effectiveness not established

    Experimental approaches: Ultrabrief bilateral ECT

    Listed as experimental in policy

    Experimental approaches: Adjunctive ketamine in ECT

    Effectiveness not established; evidence mixed

    Experimental approaches: Functional MRI of fronto-temporal connectivity to predict ECT outcome

    Not established for clinical use

    Experimental approaches: Measurement of plasma BDNF as an indicator of ECT response

    Predictive value not established

    Experimental indications: ECT for the following indications: addictive disorders (e.g., methamphetamine dependence), autism spectrum disorders, autoimmune encephalitis (eg, anti-NMDA receptor encephalitis), body dysmorphic disorder, complex regional pain syndrome, delirium, dementia-associated agitation and aggression, drug-resistant epilepsy, eating disorders, Lennox-Gastaut syndrome, motor symptoms of Parkinson disease, neuropsychiatric complications of COVID-19, obsessive-compulsive disorder, post‑traumatic stress disorder, refractory status epilepticus, self-injurious behaviors, somatic symptom disorder, tardive dyskinesias/tardive syndromes, Tourette syndrome, and treatment‑resistant schizophrenia.

    List from policy; these uses are considered experimental/investigational

    Experimental cognitive-enhancer strategies: Use of ketamine, liothyronine, melatonin, opioid receptor agonists, piracetam, and prophylactic cognitive enhancers (eg, cholinesterase inhibitors and memantine) to improve cognitive function during ECT

    Effectiveness not established

    Experimental EEG prediction: Use of EEG to predict clinical response to ECT in individuals with major depression

    Not established for routine clinical use

    Evidence-based coverage considerations by indication

    Evidence summaries and considerations by indication

    Treatment-resistant schizophrenia (ECT augmentation): Systematic reviews and meta-analyses report that adding ECT to antipsychotics may increase rates of clinical improvement (GRADE: moderate for some outcomes), but trials are heterogeneous and many are at high risk of bias; adverse events (eg, headache, memory impairment) were more frequent in combined treatment groups.

    Mean ECT number for clozapine augmentation reported ~11.3; controlled data limited

    Refractory status epilepticus (salvage therapy): Retrospective series report seizure reduction/control in a proportion of patients (eg, pooled series n=19 with ~57.9% seizure reduction/control) but evidence is Oxford level 4/GRADE D; routine use cannot be recommended without further study.

    Consider only after exhaustion of standard therapies and in research/compassionate settings

    Dementia-associated agitation/aggression: Case series and systematic reviews (totaling ~216 patients in some reviews) suggest ECT may reduce agitation/aggression in severe, treatment-refractory dementia; evidence limited by retrospective designs, concomitant medications, and short follow-up; maintenance ECT reported to help relapsing patients.

    Document objective agitation scales and consider risks of postictal confusion

    Adjunctive ketamine with ECT: Randomized trials and meta-analyses provide mixed results; some trials show no benefit and higher rates of acute confusion/disorientation; overall evidence does not support routine ketamine augmentation of ECT.

    Use cautiously; document cardiac history due to transient BP elevations reported with ketamine

    Other indications with limited evidence: For indications such as Tourette syndrome, autism spectrum disorders (catatonia), and addiction, available data are limited to case reports or small series and do not establish effectiveness; ECT is not supported for methamphetamine dependence.

    These uses generally considered investigational

    Indications supported by cited evidence

    Clinical indications where ECT has reported benefit in the cited literature (evidence type noted):

    Dementia-associated agitation/aggression: Multiple case series and systematic reviews report clinically significant reductions in agitation/aggression after ECT (evidence: case series, retrospective reviews, limited prospective data).evidence: case series/retrospective

    Authors call for prospective studies; maintenance ECT may prevent relapse

    Post-traumatic stress disorder (PTSD): A small open prospective study (n=20) of medication- and CBT-refractory chronic PTSD reported substantial CAPS score improvements after 6 bilateral ECT sessions (evidence: small uncontrolled study); systematic reviews note limited and mixed evidence.evidence: small uncontrolled study

    RCTs needed to clarify efficacy

    Autoimmune encephalitis with psychiatric catatonia (eg, anti-NMDA receptor encephalitis): Multiple case reports and small series describe safe and effective use of ECT for catatonia and severe psychiatric symptoms in anti-NMDA receptor encephalitis (evidence: case reports/series).evidence: case reports/series

    No controlled data available

    Lennox-Gastaut syndrome and drug-resistant epilepsy: A small open-label pilot (n=7) found no consistent seizure reduction and some adverse behavioral effects; not supportive of efficacy for seizure reduction (evidence: pilot study).evidence: pilot study

    Safety acceptable but efficacy not demonstrated

    Somatic symptom disorder with comorbid major depression: Case reports suggest ECT may improve somatic symptoms when SSD co-occurs with major depressive disorder (evidence: case reports).evidence: case reports

    Further research needed

    Agitation in schizophrenia: Meta-analysis of RCTs (largely low quality) found no clear advantage of ECT over antipsychotic monotherapy for agitation outcomes, though some reductions in PANSS total scores were observed (evidence: low-quality RCTs).evidence: low-quality RCTs

    Higher-quality trials needed

    Obsessive‑compulsive related disorders, tic disorders, self‑injurious behaviors: Case reports/series (n=69) reported ~73% positive response across OCRDs, tic disorders, and self-injurious behaviors, but relapse was common without maintenance ECT (evidence: case reports/series).evidence: case reports/series

    RCTs may be warranted for severe refractory cases

    Eating disorders: Limited literature (14 patients) reported improvement in most cases treated with ECT; safety appeared acceptable but evidence is insufficient to guide routine use (evidence: small case series/reports).evidence: limited case reports/series

    More research needed

    Biomarker and predictor studies: Exploratory studies (fMRI connectivity, EEG measures, plasma BDNF) report potential predictive signals for ECT response but findings are inconsistent and require larger validation studies (evidence: exploratory/small studies).evidence: exploratory studies

    Not established for clinical decision-making

    The policy lists specific ICD-10 codes not covered for indications in this Clinical Policy Bulletin. Examples include codes for dementia (e.g., F01.50–F03.C4), mild neurocognitive disorder due to known physiologic condition (F06.70–F06.71), substance-related and addictive disorders (F10.10–F19.99), anxiety and related disorders (F40.00–F48.9), eating disorders (F50.00–F50.9), specific personality disorders (F60.0–F60.9), pervasive developmental disorders (F84.0–F84.9), and tic disorders (F95.0–F95.9). The document also lists neurologic and movement disorder codes among non-covered examples, such as autoimmune encephalitis (G04.81), Parkinson disease (G20), and multiple epilepsy/status epilepticus codes (various G40.x entries).

    A focused review concluded there is no scientific evidence supporting ECT as a treatment for methamphetamine dependence; authors characterized reported use in this context as unsupported and described it as unethical, noting the absence of justification for ECT in addictive disorders.

    A small open-label pilot of adjunctive ECT for Lennox–Gastaut syndrome (n = 7) did not demonstrate consistent seizure reduction: only one patient achieved >50% seizure reduction while another experienced increased seizures; some patients had behavioral adverse effects. The authors concluded adjunctive ECT was not effective for decreasing seizure frequency in this limited pilot sample.

    Limitations of the evidence are repeatedly emphasized: randomized trials and reviews include a small number of RCTs, populations and outcome definitions are heterogeneous, ECT techniques (electrode placement, stimulus dosing, pulse width) vary across studies, and post‑ECT cognitive assessment methods are imperfect. These issues limit generalizability and confidence in conclusions about both efficacy and cognitive safety.

    For delirium, systematic review evidence is very limited and of low quality (case reports, case series, one quasi‑experimental study; total n ≈ 40). Although some individual reports described improvement, objective outcome measures were often missing and methodological bias was common. Review authors concluded there is insufficient evidence to consider modified ECT an established, evidence‑based or safe treatment for delirium.

    The policy states that ECT is not effective for chronic schizophrenia and is not considered an indication for a range of disorders, including body dysmorphic disorder, dysthymic disorder, neuroses, dissociative disorders, hypochondriasis, conversion disorder, substance‑related disorders, and personality disorders.

    A meta-analysis addressing agitation outcomes in schizophrenia identified seven low‑quality, nonblinded RCTs. Pooled data showed no significant advantage of ECT alone or combined with antipsychotics versus antipsychotic monotherapy for the agitation subscore of PANSS, although some analyses found improvements in PANSS total score. Overall evidence was rated low/very low quality.

    The review of ECT for delirium noted that available reports describe transient AEs (mild confusion, reversible memory deficits) but suffer from selection, publication and reporting bias and generally lack robust safety data. Because the evidence is limited and of poor quality, modified ECT for delirium is not established as evidence‑based or proven safe and therefore is not supported as a standard clinical practice.

    Coding and Visit Limits

    CPT codes covered if selection criteria are metCPTCovered
    00104Anesthesia for electroconvulsive therapy.
    90870Electroconvulsive therapy (includes necessary monitoring) [not covered for ultrabrief bilateral electroconvulsive therapy].
    CPT codes not covered for indications listed in the CPBCPTNot Covered
    70554Magnetic resonance imaging, brain, functional MRI; including test selection and administration of repetitive body part movement and/or visual stimulation, not requiring physician or psychologist administration.
    70555Magnetic resonance imaging, brain, functional MRI; requiring physician or psychologist administration of entire neurofunctional testing.
    ICD-10 codes covered if selection criteria are metICD-10Covered
    F06.1Catatonic disorder due to known physiological condition.
    F20.0-F20.9Schizophrenia [covered for acute exacerbations only].
    F25.0-F25.9Schizoaffective disorder.
    F30.10-F30.9Manic episode.
    F31.0-F31.9Bipolar disorder.
    F32.0-F33.9Major depressive disorder.
    F34.1Dysthymic disorder.
    ICD-10 codes not covered for indications listed in the CPB (not all-inclusive)ICD-10Not Covered
    F01.50-F03.C4Dementia.
    F06.70-F06.71Mild neurocognitive disorder due to known physiological condition.
    F10.10-F19.99Mental and behavioral disorders due to psychoactive substance use [addictive disorders].
    F40.00-F48.9Anxiety, dissociative, stress-related, somatoform and other non-psychotic disorders.
    F50.00-F50.9Eating disorders.
    F60.0-F60.9Specific personality disorders.
    F84.0-F84.9Pervasive developmental disorders.
    F95.0-F95.9Tic disorder.
    G04.81Other encephalitis and encephalomyelitis [autoimmune encephalitis (e.g., anti-NMDA receptor encephalitis)].
    G20Parkinson's disease.
    1–10 of 18
    1/2
    Maximum typical number of sessions in a series
    Maximum typical sessions per treatment seriesMore than 20 sessions in a treatment series is rarely medically necessary; additional less‑frequent prophylactic sessions may continue after remission
    Typical course for major depressionAverage course 6–12 treatments; some patients may require up to 20 treatments
    Stopping rules (clinical experience)Discontinue if no change after 2 additional treatments following partial improvement, or if no response after 6–10 treatments
    Prophylactic/maintenance schedulingAfter remission, prophylactic ECT often begins weekly then decreases to monthly or less; durations reported from 4–6 months to several years
    Note on indefinite prophylaxisSome patients may require indefinite prophylactic ECT with gradually decreased frequency
    ECT sessions — Typical scheduling
    Typical frequency per weekECT is usually administered 2–3 times per week
    Possible daily administrationECT may be administered daily if tolerated in select clinical situations
    Inpatient vs outpatient settingECT is generally administered inpatient but can be outpatient in facilities with treatment and recovery rooms
    ECT sessions — Clozapine augmentation (TRS)
    Mean number of treatments for clozapine augmentationMean 11.3 ECT treatments reported for augmentation of clozapine in TRS series
    Pooled response proportion (C+ECT)Pooled response to clozapine plus ECT ~54% in small pooled trials (95% CI: 21.8–83.6%)
    Relapse after cessation32% of cases with follow-up relapsed after stopping ECT (based on cases with follow-up data)
    Adverse events proportionAdverse events reported in 14% of identified C+ECT cases
    ECT sessions — Dementia-associated agitation series
    Mean number of treatments in dementia agitation seriesPatients received a mean of 9 ECT treatments (mostly bilateral) in the reported series
    Primary outcome improvementsSignificant reductions in Pittsburgh Agitation Scale (from 11.0 ±5.0 to 3.9 ±4.3) and Clinical Global Impression scores reported
    Postictal confusion frequency8 of 16 patients had transient postictal confusion (typically resolved within 48 hours); 2 required treatment modification
    Sample and follow-upSeries included 16 dementia patients (mean age 66.6 ±8.3); authors recommended further prospective studies

    Prior Authorization, Documentation, and Billing Guidance

    Prior Authorization

    Prior authorization: CPT 00104 and 90870 require medical necessity

    CPT 00104 (anesthesia for ECT) and 90870 (ECT) are covered only when the policy's selection criteria/medical necessity are met; coverage is contingent on documentation of an indicated diagnosis and clinical need.

    Prior Authorization

    Prior authorization: document prior trials for ECT in TRS

    When ECT is used for treatment‑resistant schizophrenia or as augmentation of clozapine, clinical notes should document prior trials, definition of treatment resistance, and the rationale for ECT (evidence supports possible benefit but trials are limited).

    Prior Authorization

    Prior authorization recommended for off‑label or low‑evidence indications

    For indications with limited or low‑quality evidence (for example dementia‑associated agitation and many case series), prior authorization should document failure of standard behavioral, environmental, and pharmacologic interventions and explain rationale for ECT as rescue or adjunctive therapy.

    Note

    Prior authorization not explicitly specified in excerpts

    These excerpts do not specify a distinct prior authorization process; individual plan prior authorization requirements are determined by the member's plan.

    Prior Authorization

    Prior authorization: confirm age ≥12 and selection criteria

    Prior authorization review should confirm the Appendix selection criteria: member age ≥ 12, a qualifying psychiatric diagnosis, and that at least one selection criterion is met (e.g., failed adequate medication trial, intolerance/contraindication, prior favorable ECT response, urgent risk, pregnancy, or informed patient preference).

    Note

    Plan‑level determination of prior authorization requirements

    This Clinical Policy Bulletin is intended to assist in administering plan benefits and notes review history; prior authorization requirements themselves are determined by the member's plan.

    Step Therapy

    Therapy sequencing: ECT after medication failure or for urgent cases

    ECT is usually considered when medications fail, cannot be tolerated, or are dangerous; it may be first‑line for severely depressed patients requiring rapid response (e.g., high suicide risk, stupor, life‑threatening inanition).

    Documentation Required

    Document prior conservative therapies before ECT when applicable

    Document trials of standard pharmacologic and behavioral therapies where applicable (e.g., antipsychotics or alpha‑2 agonists for tic disorders, antidepressants/CBT for PTSD) before electing ECT for conditions with established alternatives.

    Step Therapy

    Expect stepwise treatment prior to ECT in refractory conditions

    Evidence summaries emphasize that ECT is often used after failure of behavioral and pharmacologic therapies (for example in severe dementia agitation or CBT/medication‑refractory PTSD), supporting a stepwise approach before ECT.

    Documentation Required

    Document consideration of continuation pharmacotherapy after ECT

    Continuation pharmacotherapy (for example lithium) after a successful ECT course has been associated with reduced relapse risk in some studies; document plans for relapse prevention when applicable.

    Step Therapy

    Step therapy expectation: prior adequate medication trials expected

    Policy expects prior adequate medication trials when applicable—members should be unresponsive to effective medications given at adequate dose and duration unless an exception applies (e.g., contraindication, urgent risk, pregnancy, prior ECT response, patient preference).

    Note

    Provider action placeholder

    —

    Documentation Required

    Document supporting diagnosis for covered CPT codes

    Documentation must support that the CPT codes billed correspond to one of the medically necessary diagnoses listed in the policy (for example catatonia, acute schizophrenic exacerbation, major depressive disorder, bipolar disorder, or mania).

    Documentation Required

    Document objective ratings and treatment details for dementia agitation ECT

    For dementia‑associated agitation/aggression, include baseline and post‑ECT objective ratings (e.g., Pittsburgh Agitation Scale, CGI), number and laterality of treatments, and adverse events such as postictal confusion.

    Documentation Required

    Suggested supporting documentation: prior treatments, scales, and ECT course

    Clinical documentation should include diagnosis, prior treatments attempted and failed (pharmacologic and behavioral), objective rating scales when available (e.g., PANSS, MADRS, CAPS, Pittsburgh Agitation Scale), and the course and number of ECT treatments administered.

    Documentation Required

    If used, document EEG predictive test results for ECT response

    Resting‑state EEG features (e.g., transfer entropy, alpha‑band connectivity) have been reported as predictive tests for ECT response in research; if used clinically, document EEG findings and prediction model results to support decision‑making.

    Documentation Required

    Required documentation: age ≥12, qualifying diagnosis, and selection criterion

    Required documentation for ECT selection: confirm member is ≥12 years old, has a qualifying psychiatric diagnosis, and meets at least one selection criterion (failed adequate medication trial, medication intolerance/contraindication, prior favorable ECT response, urgent risk, severe peripartum illness, or informed patient preference).

    Documentation Required

    Provider responsibility: follow plan‑specific documentation and benefit rules

    Treating providers are responsible for medical advice and treatment; the bulletin provides guidance to assist benefit administration but does not replace plan‑specific documentation and benefit rules.

    Denial Risk

    Denial risk: non‑covered indications may be denied

    Procedures that do not meet the policy's selection criteria (i.e., indications outside the listed medically necessary diagnoses) may be denied.

    Denial Risk

    Denial risk: document risks and rationale when using adjunctive agents (e.g., ketamine)

    Use of adjunctive agents such as ketamine with ECT has mixed and inconclusive evidence and has been associated with higher rates of confusion/disorientation in RCT meta‑analysis—lack of supporting documentation may trigger coverage challenges.

    Denial Risk

    Denial risk: evidence limitations may lead to non‑coverage

    Because many studies are small, retrospective, use inconsistent rating scales, and carry selection bias, insufficient high‑quality evidence for a given indication may lead to determinations that coverage is not supported.

    Note

    No explicit authorization/billing triggers in excerpts

    No explicit authorization or billing denial triggers are described in these excerpts; the content summarizes clinical studies and reviews rather than administrative triggers.

    Denial Risk

    Denial risk: missing selection criteria or age <12

    Lack of a documented qualifying psychiatric condition, age under 12, or missing documentation that at least one selection criterion is met (for example prior adequate medication trial or contraindication) may trigger coverage denial.

    Note

    Coverage governance: CPB guides benefits but does not guarantee coverage

    Clinical Policy Bulletins are developed to assist in administering plan benefits and do not constitute offers of coverage; coverage determinations and plan benefits are governed by the member's plan documents.

    ECT Modalities, Adjuncts, and Predictive Assessments

    ECT with adjunctive ketamine

    Ketamine as adjunct/anesthetic for ECT: Randomized and meta‑analytic data are mixed: non‑ECT ketamine trials show rapid antidepressant effects, but RCTs of ketamine augmentation in ECT do not show clear clinical benefit and report increased rates of confusion/disorientation; routine use of ketamine with ECT is not established and is listed as experimental/investigational in the policy.

    Document cardiac history if used; use cautiously due to risk of acute confusion.

    ECT augmentation

    ECT augmentation of antipsychotics (including clozapine): Meta‑analyses report higher rates of clinical improvement when ECT is added to antipsychotics in refractory schizophrenia, though trials vary in quality; ECT augmentation of clozapine has reported pooled response proportion (~54%) and may require more treatments (mean ~11.3); consider for treatment‑resistant schizophrenia after documented inadequate trials of medications.

    Adverse events and cognitive effects reported; evidence heterogeneity and limited controlled data noted.

    ECT

    ECT for severe, refractory neuropsychiatric presentations: Case series and reviews describe ECT use for catatonia (including in autoimmune encephalitis), severe dementia‑associated agitation and aggression, and other refractory neuropsychiatric syndromes; evidence is often limited to case series and small observational studies, supporting consideration of ECT in selected refractory cases with specialist oversight.

    Document prior treatments, objective rating scales when available, and rationale for ECT.

    ECT adjunctive pharmacotherapy

    Pharmacologic adjuncts to reduce cognitive side effects: Systematic reviews identify memantine and liothyronine as having low‑quality evidence of effectiveness for diminishing cognitive side effects of ECT; other agents (acetylcholine inhibitors, piracetam, melatonin) have very low‑quality evidence in some domains; ketamine and opioid agonists show no effectiveness for this purpose.

    Evidence quality low; interventions remain investigational for routine prophylaxis.

    ECT biomarker assessment (EEG)

    Resting‑state EEG and connectivity measures: Small studies report that resting‑state EEG features (e.g., transfer entropy, alpha‑band connectivity, P300 amplitude, delta coherence) can predict ECT response with promising but not yet validated accuracy; current evidence is exploratory and requires prospective multicenter validation before routine clinical use.research/experimental

    If used clinically, document EEG features and prediction model results to support decision‑making.

    ECT with baseline EEG predictors

    Baseline EEG predictive markers: Baseline EEG markers (P300 amplitude, delta coherence, alpha‑2 band linear lagged connectivity and other connectivity/coherence measures) have been associated with treatment outcome in small studies, but findings are heterogeneous and not standardized—considered research/experimental at present.research/experimental

    Further prospective studies needed prior to clinical adoption.

    Continuation/Maintenance ECT (C/M‑ECT)

    Continuation / Maintenance ECT: Continuation/maintenance ECT (C/M‑ECT) may reduce relapse rates in selected patients with severe or treatment‑resistant depression (evidence from observational studies and some controlled trials; overall certainty low/very low); discuss uncertain long‑term cognitive effects with patients when considering C/M‑ECT.clinical judgment

    Evidence suggests relapse reduction in some studies (14/20 studies showing benefit); standardized cognitive assessment data limited.

    ECT with adjunctive ketamine (references)

    Adjunctive ketamine references and guidance: References and trials of ketamine as an anesthetic or adjunct in ECT report mixed results; several RCTs and meta‑analyses found no clear benefit and higher rates of acute confusion/disorientation—routine adjunctive ketamine is not established and is listed as experimental/investigational in the policy.

    If ketamine is used, document rationale, prior failures, and monitor for confusion/disorientation.

    Inpatient and Outpatient Level of Care

    Key Definitions

    Definition — Electroconvulsive therapy (ECT)
    DefinitionElectroconvulsive therapy (ECT) involves intentional induction of generalized seizures by administering electrical impulses to an anesthetized patient
    PersonnelTreatments are typically administered by a psychiatrist and an anesthesiologist or anesthetist
    SettingGenerally inpatient but may be outpatient in facilities with treatment and recovery rooms
    Definition — Refractory status epilepticus (RSE)
    DefinitionRefractory status epilepticus (RSE): status epilepticus not controlled with standard medical treatments; ECT has been reported as a salvage therapy in small retrospective series
    Evidence summarySystematic review identified 14 articles (19 patients) with seizure reduction/control in 11 of 19 patients (57.9%), but studies were retrospective (Oxford level 4, GRADE D)
    Clinical cautionRoutine use of ECT for RSE cannot be recommended; consider only after exhaustion of standard therapies and in research/compassionate contexts
    Definition — Treatment‑resistant schizophrenia (TRS)
    DefinitionTreatment‑resistant schizophrenia (TRS): schizophrenia not adequately responsive to standard antipsychotic therapy; ECT has been evaluated as augmentation to antipsychotics (including clozapine)
    Mean ECT numberMean number of ECT treatments reported to augment clozapine was 11.3 in pooled analyses
    Evidence characteristicsPooled data include small RCTs and open‑label trials with heterogeneity and limited controlled evidence
    Definition — Dementia‑associated agitation/aggression
    DefinitionDementia‑associated agitation/aggression: severe behavioral disturbance in major neurocognitive disorder characterized by agitation or aggression refractory to standard behavioral and pharmacologic interventions
    Evidence summaryCase series and systematic reviews (total ~216 patients) report reductions in agitation with ECT, but studies are limited by design and short follow-up
    Treatment courseReported mean number of ECT treatments in series is about 9; maintenance ECT may benefit relapsing patients
    Definition — Refractory PTSD
    DefinitionRefractory PTSD: PTSD that has failed adequate trials of multiple antidepressants and a course of cognitive behavioral therapy as defined in the cited prospective study
    Study exampleOpen prospective study treated 20 patients with 6 bilateral ECT sessions twice weekly; response rate 70% (intent‑to‑treat) with maintained gains at 4–6 month follow‑up
    Evidence cautionAvailable evidence is limited and mixed; RCTs are needed to clarify efficacy separate from effects on depression
    Definition — Transfer entropy (TE) (EEG measure)
    DefinitionTransfer entropy (TE): an EEG‑derived measure representing information flow extracted from baseline resting‑state EEG used as a feature to predict individual ECT response
    Predictive performanceIn one study using TE in resting‑state EEG, a predictive model classified responders with ~85% balanced accuracy (sensitivity 88.7%, specificity 81.8%)
    Research statusPromising in small studies but requires rigorous prospective validation before routine clinical adoption
    Definition — Alpha 2 band linear lagged connectivity (EEG measure)
    DefinitionAlpha‑2 band linear lagged connectivity: an EEG connectivity measure within the alpha frequency sub‑band found to be lower in responders versus non‑responders and correlated with clinical global impression scores
    Study contextRetrospective resting‑state EEG analyses using LORETA and NBS approaches identified reduced alpha‑2 connectivity in responders
    Clinical implicationMay serve as a predictive biomarker for ECT response pending prospective, multi‑center validation
    Definition — Continuation/Maintenance ECT (C/M‑ECT)
    DefinitionContinuation/Maintenance ECT (C/M‑ECT): repeated ECT sessions administered after an index course to prevent relapse of depression
    Evidence summarySystematic review of 20 studies found evidence from 14 studies suggesting reduced relapse with C/M‑ECT, but certainty of evidence low/very low
    Clinical useConsidered a viable option for selected patients with severe or treatment‑resistant depression after discussion of uncertain long‑term cognitive effects
    Definition — Baseline EEG predictors
    DefinitionBaseline EEG predictors: pre‑treatment EEG markers (e.g., P300 amplitude, delta coherence, alpha‑2 band connectivity, TE) proposed to predict likelihood of clinical response or remission to ECT
    Evidence baseSystematic reviews identified ~12 studies with heterogeneous methods showing correlations between EEG markers and response; further prospective studies needed
    Clinical statusExploratory/research; not yet standardized for routine clinical decision‑making
    Definition — Clinical Policy Bulletin
    DefinitionClinical Policy Bulletin: an Aetna document developed to assist in administering plan benefits; not a contract or medical advice
    Policy identifiersPolicy number 0445; Effective date 09/14/2000; Last review 09/21/2023; Next review 05/09/2024
    ScopeProvides coverage stance, selection criteria, experimental/investigational list, and coding guidance for ECT

    Background: ECT is a procedure in which clinicians intentionally induce a generalized seizure under general anesthesia. It is typically administered 2–3 times weekly during an index course, and for major depressive disorder typical courses are reported as 6–12 treatments although some patients may require up to about 20 treatments in a series. ECT may be delivered with varying electrode placements and pulse widths (brief pulse, ultrabrief, bilateral/unilateral), which affect both efficacy and cognitive outcomes.